Related Experiment Video
Updated: Aug 13, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Combined therapy with tetrabenazine and pimozide in Huntington's chorea: pilot study
The New Zealand Medical Journal
|February 25, 1976
Summary
Current Huntington's chorea treatments targeting acetylcholine and dopamine are unsatisfactory. A trial of dopamine antagonists tetrabenazine and pimozide showed initial improvement, but benefits were not sustained over 83 weeks.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Huntington's chorea treatments targeting acetylcholine and dopamine in basal ganglia are currently unsatisfactory.
- There is a need for more effective therapeutic strategies for managing chorea symptoms.
Purpose of the Study:
- To evaluate the efficacy and durability of dopamine antagonists, specifically tetrabenazine and pimozide, in treating Huntington's chorea.
Main Methods:
- A small clinical trial was conducted involving patients with Huntington's chorea.
- Participants were treated with tetrabenazine (Nitoman) and pimozide (Orap), both dopamine antagonists.
Main Results:
- An early and striking improvement in chorea symptoms was observed in participants.
- However, this improvement was not maintained throughout the entire 83-week trial period.
Conclusions:
- Dopamine antagonists like tetrabenazine and pimozide demonstrate initial efficacy in managing Huntington's chorea.
- The lack of sustained improvement suggests limitations in their long-term therapeutic value for this condition.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...